NCT02370693View on ClinicalTrials.gov

Comparing and Combining Bortezomib and Mycophenolate in SSc Pulmonary Fibrosis

PHASE2CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

March 31, 2016

Primary Completion Date

December 16, 2019

Study Completion Date

January 1, 2020

Conditions
Lung Diseases, InterstitialSystemic SclerosisScleroderma
Interventions
DRUG

Bortezomib

Bortezomib 1.3 mg/m² subcutaneously (or IV push if unable to tolerate subcutaneous injection) once per week for the first two weeks per month for 24 weeks

DRUG

Placebo

Placebo (normal saline) 1.3 mg/m² subcutaneously (or IV push if unable to tolerate subcutaneous injection) once per week for the first two weeks per month for 24 weeks

DRUG

Mycophenolate mofetil

Mycophenolate mofetil 1.5 g twice a day orally for 24 weeks

Trial Locations (1)

60611

Northwestern University, Chicago

All Listed Sponsors
collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

lead

Northwestern University

OTHER

NCT02370693 - Comparing and Combining Bortezomib and Mycophenolate in SSc Pulmonary Fibrosis | Biotech Hunter | Biotech Hunter